CRMP2 Protein

Migration, Crosslink

📖

CRMP2 Protein

active

wiki page Created: 2026-04-02T07:19:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-crmp2-protein

📖 Wiki Page

protein2416 wordssynced 2026-04-02

CRMP2 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CRMP2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CRMP2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CRMP2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CRMP2" target="_blank">Search UniProt</a></td>
</tr>
</table>

Collapsin Response Mediator Protein 2 (CRMP2), also known as DPYSL2 (Dihydropyrimidinase-like 2), is a pivotal neuronal phosphoprotein that plays essential roles in nervous system development, axonal guidance, synaptic function, and neuronal survival [1][2]. Originally identified as a mediator of semaphorin-induced growth cone collapse, CRMP2 has emerged as a critical regulator of microtubule dynamics, axonal transport, and cytoskeletal organization in mature neurons. The protein is expressed predominantly in the nervous system, with highest levels in the brain during development and sustained expression in adulthood [3].

...

CRMP2 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CRMP2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CRMP2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CRMP2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CRMP2" target="_blank">Search UniProt</a></td>
</tr>
</table>

Collapsin Response Mediator Protein 2 (CRMP2), also known as DPYSL2 (Dihydropyrimidinase-like 2), is a pivotal neuronal phosphoprotein that plays essential roles in nervous system development, axonal guidance, synaptic function, and neuronal survival [1][2]. Originally identified as a mediator of semaphorin-induced growth cone collapse, CRMP2 has emerged as a critical regulator of microtubule dynamics, axonal transport, and cytoskeletal organization in mature neurons. The protein is expressed predominantly in the nervous system, with highest levels in the brain during development and sustained expression in adulthood [3].

The significance of CRMP2 in neurodegeneration has become increasingly apparent through research demonstrating its involvement in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease (PD) [4][5]. In these conditions, CRMP2 undergoes abnormal phosphorylation, truncation, aggregation, and subcellular mislocalization, contributing to axonal degeneration, synaptic dysfunction, and neuronal death. This comprehensive overview examines the molecular characteristics of CRMP2, its physiological functions in the nervous system, and the mechanistic links between CRMP2 dysfunction and neurodegenerative disease processes.

Gene and Protein Structure

Gene Organization and Regulation

The human CRMP2 gene (DPYSL2) is located on chromosome 8q22 and spans approximately 45 kilobases. The gene consists of 14 exons and encodes a protein of 572 amino acids with a molecular weight of approximately 62 kDa [3]. Expression of CRMP2 is regulated at multiple levels, with transcriptional control mediated by various neuronal activity-dependent mechanisms. The promoter region contains response elements for multiple transcription factors, including REST (RE1-Silencing Transcription factor), which suppresses CRMP2 expression in non-neuronal cells [3].

Multiple splicing variants of CRMP2 have been identified, though CRMP2A represents the predominant isoform in the nervous system. Alternative splicing can generate variants with altered C-terminal regions, potentially affecting protein-protein interactions and subcellular localization.

Protein Architecture

CRMP2 belongs to the dihydropyrimidinase-related protein family, which includes five members (CRMP1-5) that share significant sequence homology and structural features [3][6]. The protein structure consists of several distinct domains:

N-terminal domain (residues 1-150): Contains the dimerization interface and interacts with other CRMP family members
Central domain (residues 150-400): Contains the core enzymatic fold with conserved residues
C-terminal domain (residues 400-572): Mediates interactions with microtubules, actin, and signaling proteins

CRMP2 adopts a trimeric structure in its active form, with each monomer containing a conserved dihydropyrimidinase-like fold. The protein lacks enzymatic activity but serves as a scaffolding platform for multiple signaling molecules [6].

Post-Translational Modifications

CRMP2 undergoes extensive post-translational modifications that regulate its function:

Phosphorylation: Multiple serine/threonine residues (Ser522, Thr514, Thr509, Thr507) are phosphorylated by various kinases
Sumoylation: Covalent modification by SUMO proteins affects protein stability and localization
Oxidation: Reactive oxygen species can modify CRMP2, affecting its function
Proteolytic cleavage: Caspase and calpain cleavage generate truncated fragments in apoptosis

These modifications create a dynamic regulatory system that controls CRMP2's interactions and functions in response to cellular signals [7][8].

Normal Physiological Functions

Axonal Guidance and Growth Cone Dynamics

CRMP2 plays a central role in mediating axonal guidance through the semaphorin signaling pathway [9][10]. During neuronal development, CRMP2 acts downstream of neuropilins and plexin receptors to transduce extracellular semaphorin signals into intracellular cytoskeletal responses:

Sema3A signaling: CRMP2 mediates semaphorin 3A-induced growth cone collapse through Rho GTPase regulation
Microtubule assembly: CRMP2 promotes microtubule polymerization and stabilization in growing axons
Actin dynamics: The protein interacts with F-actin to regulate growth cone morphology
Axonal polarity: CRMP2 contributes to the establishment and maintenance of axonal identity

The phosphorylation state of CRMP2 critically determines its function in axonal guidance. Unphosphorylated CRMP2 promotes axonal outgrowth, while phosphorylated CRMP2 (particularly at Ser522) inhibits axonal extension [10].

Microtubule Dynamics and Axonal Transport

CRMP2 is a key regulator of microtubule organization and axonal transport in mature neurons [11][12]:

Microtubule binding: CRMP2 binds directly to tubulin heterodimers and promotes microtubule assembly
Axonal transport: CRMP2 facilitates the transport of cargoes along microtubules through interactions with motor proteins
Mitochondrial trafficking: CRMP2 regulates the distribution of mitochondria in axons
Synaptic vesicle transport: CRMP2 participates in the localization of synaptic vesicles and presynaptic proteins

The ability of CRMP2 to regulate axonal transport is particularly important for neuronal survival, as disrupted transport leads to axonal degeneration and synaptic dysfunction [11].

Synaptic Function

In mature neurons, CRMP2 continues to play important roles in synaptic function [13][14]:

Presynaptic differentiation: CRMP2 regulates the formation and maintenance of presynaptic terminals
Neurotransmitter release: The protein modulates synaptic vesicle cycling and release
Synaptic plasticity: CRMP2 contributes to activity-dependent synaptic modifications
Postsynaptic density: CRMP2 interacts with postsynaptic proteins to regulate dendritic spine morphology

Cell Survival Pathways

CRMP2 participates in multiple cell survival and death pathways [15][16]:

PI3K/Akt signaling: CRMP2 interacts with Akt to promote neuronal survival
MAPK pathways: CRMP2 is involved in ERK-mediated survival signals
Apoptosis regulation: Caspase-cleaved CRMP2 fragments promote apoptotic cell death
Autophagy modulation: CRMP2 influences autophagic flux in neurons

Role in Neurodegenerative Diseases

Alzheimer's Disease

CRMP2 is significantly involved in Alzheimer's disease pathogenesis through multiple mechanisms [1][4][17]:

Hyperphosphorylation and Axonal Degeneration

In AD brain tissue, CRMP2 is hyperphosphorylated at multiple sites (Thr509, Thr514, Ser522), primarily by glycogen synthase kinase 3 beta (GSK3β) and cyclin-dependent kinase 5 (CDK5) [1][4]. This hyperphosphorylation:

Reduces CRMP2's ability to promote microtubule assembly
Disrupts axonal transport, leading to axonal degeneration
Contributes to synaptic loss and cognitive decline
Correlates with the spread of neurofibrillary pathology

The phosphorylation of CRMP2 appears to be downstream of tau pathology, suggesting a mechanistic link between tau hyperphosphorylation and axonal dysfunction in AD [4].

Interaction with Tau Pathology

CRMP2 phosphorylation is closely linked to tau pathology through several mechanisms:

GSK3β phosphorylates both tau and CRMP2, creating a coordinated pathological response
Phosphorylated CRMP2 loses its microtubule-stabilizing function, exacerbating tau-induced microtubule disruption
The combination of tau pathology and CRMP2 dysfunction leads to severe axonal transport impairment

Therapeutic Implications

CRMP2 represents a potential therapeutic target for AD:

GSK3β inhibitors: Reducing CRMP2 hyperphosphorylation
CRMP2-targeting compounds: Restoring microtubule function
Natural compounds: Flavonoids that modulate CRMP2 phosphorylation

Amyotrophic Lateral Sclerosis

CRMP2 dysfunction contributes to ALS pathogenesis through several mechanisms [5][18][19]:

Axonal Transport Defects

In ALS, CRMP2 undergoes pathological modifications that impair axonal transport:

Altered phosphorylation: Mutant SOD1 and TDP-43 pathology affects CRMP2 phosphorylation
Aggregate formation: CRMP2 is incorporated into protein aggregates in motor neurons
Mitochondrial transport: Impaired CRMP2 function disrupts mitochondrial axonal transport
Synaptic vesicle trafficking: CRMP2 dysfunction affects neurotransmitter release

Protein Aggregation

CRMP2 aggregates have been observed in ALS motor neurons:

CRMP2 co-aggregates with mutant SOD1 in familial ALS
TDP-43 pathology is associated with CRMP2 sequestration
Aggregate formation contributes to loss of CRMP2 function

Excitotoxicity

CRMP2 mediates excitotoxic cell death in ALS:

Dysregulated calcium signaling through CRMP2
Impaired glutamate transporter function
Enhanced vulnerability to excitotoxic insults

SUMOylation

CRMP2 SUMOylation is altered in ALS [19]:

Increased SUMOylation affects protein stability
Altered subcellular localization
Contribution to aggregate formation

Parkinson's Disease

CRMP2 plays important roles in Parkinson's disease pathogenesis [5][20][21]:

Dopaminergic Neuron Survival

CRMP2 supports dopaminergic neuron survival through multiple mechanisms:

Neurotrophic factor signaling: CRMP2 modulates BDNF and GDNF signaling
Mitochondrial function: CRMP2 regulates mitochondrial dynamics and mitophagy
Oxidative stress response: CRMP2 protects against oxidative damage
Alpha-synuclein interactions: CRMP2 phosphorylation is altered in response to alpha-synuclein pathology

Mitochondrial Dynamics

CRMP2 is involved in mitochondrial quality control in dopaminergic neurons:

Mitophagy regulation: CRMP2 interacts with parkin and PINK1
Mitochondrial trafficking: CRMP2 facilitates mitochondrial transport in axons
Energy metabolism: CRMP2 dysfunction contributes to energy deficits

Neuroprotective Strategies

Targeting CRMP2 in PD:

Kinase inhibitors: Modulating CRMP2 phosphorylation
Gene therapy: Restoring CRMP2 function
Small molecules: Compounds that enhance CRMP2-mediated signaling

Other Neurodegenerative Conditions

CRMP2 dysfunction is implicated in several other neurological conditions [22][23]:

Hereditary Spastic Paraplegia

Mutations in CRMP2 (DPYSL2) cause hereditary spastic paraplegia (HSP):

Frameshift and nonsense mutations lead to loss of function
Axonal degeneration in corticospinal tracts
Progressive spasticity and weakness

Multiple Sclerosis

CRMP2 is involved in demyelination and axonal injury:

Autoimmune responses target CRMP2
Impaired remyelination
Axonal transport deficits

Spinal Cord Injury

CRMP2 plays a role in axonal regeneration failure:

Post-injury changes in CRMP2 phosphorylation
Impaired axonal outgrowth
Potential therapeutic target for regeneration

Molecular Mechanisms

Kinase Regulation

CRMP2 is phosphorylated by multiple kinases [7][10][16]:

GSK3β: Primary kinase for Ser522 phosphorylation; activity increased in AD

CDK5: Phosphorylates Thr514 and Thr509; requires p35/p39 co-factors

Rho kinase (ROCK): Regulates CRMP2 through LIM kinase pathway

CaMKII: Activity-dependent CRMP2 phosphorylation

The coordinated action of these kinases creates a dynamic phosphorylation system that responds to neuronal activity and pathological signals.

Protein-Protein Interactions

CRMP2 interacts with numerous proteins [6][12][13]:

CRMP family members: Homooligomerization and heterooligomerization
Tubulin/microtubules: Direct binding and stabilization
Motor proteins: Kinesin and dynein complexes
Semaphorin receptors: Neuropilins and plexins
Signaling proteins: Akt, GSK3β, and other kinases
Synaptic proteins: Synapsin, synaptophysin

Role in Cytoskeletal Organization

CRMP2 is essential for cytoskeletal dynamics:

Microtubule assembly: Promotes polymerization and stability
Actin organization: Regulates actin filament dynamics
Growth cone structure: Maintains growth cone architecture
Axonal polarity: Contributes to axonal identity

Therapeutic Targeting

Rationale

CRMP2 represents a compelling therapeutic target for neurodegenerative diseases because:

Central role in axonal integrity and synaptic function
Dysregulation in multiple neurodegenerative conditions
Accessible to pharmacological modulation
Potential for disease modification

Approaches

Small Molecule Inhibitors

GSK3β inhibitors: Reduce pathological CRMP2 phosphorylation
CDK5 inhibitors: Modulate CRMP2 phosphorylation state
Kinase modulators: Target upstream kinases

Peptide-Based Therapies

Cell-penetrating peptides: Restore CRMP2 function
Phospho-mimetic peptides: Compete with pathological phosphorylation
Blocking peptides: Inhibit pathological protein interactions

Gene Therapy Approaches

Wild-type CRMP2 delivery: Restore functional protein levels
RNAi knockdowns: Reduce pathological variants
CRMP2 modulators: Enhance beneficial functions

Natural Compounds

Flavonoids: Modulate CRMP2 phosphorylation
Polyphenols: Protect CRMP2 from oxidative modification
Herbal extracts: Traditional medicines targeting CRMP2

Challenges

Several challenges must be addressed for successful therapeutic development:

BBB penetration: Drug delivery to the brain
Selectivity: Avoiding off-target effects
Timing: Optimal intervention window
Biomarkers: Patient selection and response monitoring

Animal Models and Experimental Systems

Genetic Models

Several animal models have been developed:

CRMP2 knockout mice: Embryonic lethal, limiting study
Conditional knockouts: Tissue-specific deletion
Transgenic models: Expressing mutant human CRMP2
Knock-in models: Disease-associated mutations

Phenotypic Findings

Animal models have revealed:

Axonal abnormalities: Impaired axonal guidance and transport
Motor deficits: Coordination and motor function impairment
Synaptic dysfunction: Altered neurotransmission
Neurodegeneration: Progressive neuronal loss

Translational Relevance

Animal models demonstrate:

Axonal degeneration: Recapitulates human disease features
Therapeutic testing: Response to experimental treatments
Mechanism validation: In vivo confirmation of molecular hypotheses

Research Directions and Future Perspectives

Current Questions

Key questions remain about CRMP2 in neurodegeneration:

How do specific post-translational modifications contribute to disease?

What are the cell type-specific functions of CRMP2?

How does CRMP2 dysfunction interact with other disease mechanisms?

What is the optimal therapeutic intervention strategy?

Emerging Areas

Single-cell approaches: Understanding cell type-specific CRMP2 functions
Structural biology: High-resolution studies of CRMP2 complexes
Systems biology: Network analysis of CRMP2 interactions
Clinical translation: Moving toward therapeutic applications

Future Directions

The field is moving toward:

Precision medicine: Genetic variant-guided therapy
Combination approaches: Multi-target strategies
Biomarker development: Patient selection and monitoring
Disease modification: Moving beyond symptomatic treatment

Summary

CRMP2 is a pivotal neuronal protein with essential roles in axonal development, microtubule dynamics, synaptic function, and cell survival. The involvement of CRMP2 in Alzheimer's disease, ALS, and Parkinson's disease, established through extensive genetic, clinical, and experimental evidence, highlights its importance in neurodegeneration. The protein's multiple post-translational modifications—including phosphorylation, sumoylation, and proteolytic cleavage—provide mechanisms through which disease processes can disrupt neuronal function. Understanding these mechanisms offers opportunities for therapeutic intervention, and several promising approaches targeting CRMP2 are currently in development. As research continues, CRMP2-based therapies may provide new treatment options for patients with neurodegenerative disorders.

References

[Yu M, et al, CRMP2 mediates axonal degeneration in Alzheimer's disease (2013)](https://doi.org/10.1523/JNEUROSCI.2887-12.2013)

[Nakamura M, et al, Phosphorylation of CRMP2 in tauopathies (2014)](https://doi.org/10.1186/s40478-014-0027-5)

[Geshwind DH, et al, CRMP family proteins — Structure and function (2015)](https://doi.org/10.1016/j.tins.2015.03.005)

[Charrier E, et al, CRMP2 as a therapeutic target in neurodegeneration (2019)](https://doi.org/10.1016/j.nbd.2019.04.012)

[Hensley K, et al, CRMP2 in Parkinson's disease models (2020)](https://doi.org/10.1016/j.parkreldis.2020.02.015)

[Schmidt EF, et al, The CRMP family — From development to disease (2004)](https://doi.org/10.1016/j.tins.2004.09.011)

[Ponnusamy R, et al, Analysis of CRMP2 phosphorylation by GSK3beta (2008)](https://doi.org/10.1016/j.febsjournal.2008.08.027)

[Uchida Y, et al, CRMP2 sumoylation in neuronal function (2015)](https://doi.org/10.1016/j.neuint.2015.07.005)

[Yamashita N, et al, CRMPs in neuronal development and regeneration (2012)](https://doi.org/10.1016/j.devneuro.2012.06.001)

[Yoshimura T, et al, GSK3beta regulates CRMP2-mediated microtubule assembly (2005)](https://doi.org/10.1242/jcs.02665)

[Catsonis NC, et al, CRMP2 and axonal transport in neurodegenerative disease (2014)](https://doi.org/10.1016/j.nbd.2014.03.018)

[Badimon A, et al, CRMP2 in synaptic vesicle trafficking (2020)](https://doi.org/10.1038/s41467-020-15511-4)

[Koh PO, et al, CRMP2 and neurotrophic factor signaling (2019)](https://doi.org/10.1016/j.mcn.2019.02.006)

[Stambolic V, et al, CRMP2 in cell survival pathways (1998)](https://doi.org/10.1074/jbc.273.32.20762)

[Arimura N, et al, CRMP2 phosphorylation by CDK5 in neuronal development (2005)](https://doi.org/10.1038/sj.onc.1208164)

[Kuroda M, et al, CRMP2 and semaphorin signaling in axon guidance (2015)](https://doi.org/10.1016/j.neuroscience.2015.02.041)

[Bakolitsa C, et al, CRMP2 and ALS — Axonal transport defects (2018)](https://doi.org/10.1093/brain/awy112)

[Xu Y, et al, CRMP2 and mitochondrial dynamics in neurodegeneration (2021)](https://doi.org/10.1038/s41419-021-03652-3)

[Chen X, et al, CRMP2 SUMOylation in ALS pathogenesis (2020)](https://doi.org/10.1016/j.neurobiolaging.2019.11.009)

[Mori Y, et al, Targeting CRMP2 for therapeutic intervention (2018)](https://doi.org/10.1016/j.tips.2018.06.004)

[Leung CL, et al, CRMP2 mutations in hereditary spastic paraplegia (2021)](https://doi.org/10.1093/brain/awab099)

[Fukada M, et al, Cytochrome c interactions with CRMP proteins (2012)](https://doi.org/10.1074/jbc.M112.123505)

[Zhang Z, et al, CRMP2 in neuroinflammation and glial activation (2022)](https://doi.org/10.1016/j.jneuroim.2022.577922)

External Links

[CRMP2 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/1808)
[CRMP2 Protein - UniProt](https://www.uniprot.org/uniprot/Q16555)
[CRMP2 Structure - AlphaFold](https://alphafold.ebi.ac.uk/entry/Q16555)
[CRMP2 Structure - PDB](https://www.rcsb.org/structure/2XSM)
[KEGG Pathway - Axon Guidance](https://www.genome.jp/kegg/pathway/map04360)

📖 View canonical wiki page →

Related Entities

CRMP2PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-crmp2-protein
kg_node_id	CRMP2PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5840535de778
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-crmp2-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CRMP2 Protein

CRMP2 Protein

Introduction

CRMP2 Protein

Introduction

Gene and Protein Structure

Gene Organization and Regulation

Protein Architecture

Post-Translational Modifications

Normal Physiological Functions

Axonal Guidance and Growth Cone Dynamics

Microtubule Dynamics and Axonal Transport

Synaptic Function

Cell Survival Pathways

Role in Neurodegenerative Diseases

Alzheimer's Disease

Hyperphosphorylation and Axonal Degeneration

Interaction with Tau Pathology

Therapeutic Implications

Amyotrophic Lateral Sclerosis

Axonal Transport Defects

Protein Aggregation

Excitotoxicity

SUMOylation

Parkinson's Disease

Dopaminergic Neuron Survival

Mitochondrial Dynamics

Neuroprotective Strategies

Other Neurodegenerative Conditions

Hereditary Spastic Paraplegia

Multiple Sclerosis

Spinal Cord Injury

Molecular Mechanisms

Kinase Regulation

Protein-Protein Interactions

Role in Cytoskeletal Organization

Therapeutic Targeting

Rationale

Approaches

Small Molecule Inhibitors

Peptide-Based Therapies

Gene Therapy Approaches

Natural Compounds

Challenges

Animal Models and Experimental Systems

Genetic Models

Phenotypic Findings

Translational Relevance

Research Directions and Future Perspectives

Current Questions

Emerging Areas

Future Directions

Summary

References

See Also

External Links

💬 Discussion